Novavax, Inc.: Novavax COVID-19-Influenza Combination Vaccin

Trial is the first of its kind to evaluate a combined COVID-19 and influenza vaccineDose insights from Phase 1/2 trial will inform Phase 2 confirmation trial to begin in late 2022GAITHERSBURG

Related Keywords

Australia , India , Giovanna Chandler , Erika Schultz , Gregorym Glenn , Vivek Shinde , Linkedin , European Commission , Drug Administration , Prnewswire Novavax Inc , Nasdaq , World Vaccine Congress , Exchange Commission , Serum Institute Of India , Clinical Development , Novavax Inc , Influenza Combination , Vice President , Clinical Development Lead , Older Adult , Influenza Combination Vaccine Candidate Phase , Serum Institute , Financial Condition , Novavax Annual Report , Quarterly Reports , Novavax , Covid , Influenza , Combination , Vaccine , Candidate , Induced , Ntibody , Fell , Responses , Against , Cars , Homologous , Heterologous , Trains ,